{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:05:16Z","timestamp":1789733116351,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.anl.2026.09.003","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:38:03Z","timestamp":1789731483000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular targeted therapy for thyroid cancer in Japan: Current status and future perspectives"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6768-4107","authenticated-orcid":false,"given":"Sueyoshi","family":"Moritani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2026.09.003_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine- refractory,locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.anl.2026.09.003_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2026.09.003_bib3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anl.2026.09.003_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2026.09.003_bib5","first-page":"1184","article-title":"Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2026.09.003_bib6","first-page":"467","article-title":"A phase II study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan","volume":"34","author":"Tahara","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2026.09.003_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anl.2026.09.003_bib8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.anl.2026.09.003_bib9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.anl.2026.09.003_bib10","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.anl.2026.09.003_bib11","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1210\/jc.2006-2707","article-title":"BRAF mutation in papillary thyroid carcinomas inhibit genes involved in iodine metabolism","volume":"92","author":"Durante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anl.2026.09.003_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1507\/endocrj.K08E-208","article-title":"BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients","volume":"56","author":"Ito","year":"2009","journal-title":"Endocr J"},{"key":"10.1016\/j.anl.2026.09.003_bib13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/thy.2010.1646","article-title":"Genetic Alterations in the PI3K\/Akt Pathway in Thyroid Cancer","volume":"20","author":"Xing","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2026.09.003_bib14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1089\/thy.2014.0053","article-title":"NRAS Codon 61 Mutation Is Associated with Distant Metastasis in Patients with Follicular Thyroid Carcinoma","volume":"24","author":"Jang","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2026.09.003_bib15","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1172\/JCI69766","article-title":"Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers","volume":"123","author":"Ricarte-Filho","year":"2013","journal-title":"J Clin Invest"},{"issue":"25","key":"10.1016\/j.anl.2026.09.003_bib16","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2026.09.003_bib17","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/clinem\/dgae271","article-title":"Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan","volume":"109","author":"Toda","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anl.2026.09.003_bib18","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anl.2026.09.003_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113826","article-title":"The genomic and evolutionary landscapes of anaplastic thyroid carcinoma","volume":"43","author":"Zeng","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.anl.2026.09.003_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American thyroid association guidelines for the management of medullary thyroid Carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"6349","key":"10.1016\/j.anl.2026.09.003_bib21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.anl.2026.09.003_bib22","first-page":"213","article-title":"The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma - systematic review and discussion of current","volume":"25","author":"Rocha","year":"2021","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.anl.2026.09.003_bib23","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2026.09.003_bib24","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.anl.2026.09.003_bib25","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Thyroid Carcinoma. Version 2.2026","author":"National Comprehensive Cancer Network","year":"2026"},{"key":"10.1016\/j.anl.2026.09.003_bib26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejca.2017.01.013","article-title":"Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid","volume":"75","author":"Tahara","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anl.2026.09.003_bib27","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1089\/thy.2023.0553","article-title":"A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer","volume":"34","author":"Tahara","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2026.09.003_bib28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III Trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2026.09.003_bib29","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2026.09.003_bib30","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2026.09.003_bib31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2022.06.044","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)","volume":"173","author":"Higashiyama","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anl.2026.09.003_bib32","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.anl.2026.09.003_bib33","first-page":"00133","article-title":"Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, doubleblind, placebo-controlled, phase 3 trial","volume":"S1470-2045","author":"Gao","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anl.2026.09.003_bib34","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of Response With Selpercatinib in Patients With RET-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2026.09.003_bib35","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients With NTRK Fusion-Positive Solid Tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2026.09.003_bib36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1507\/endocrj.EJ24-0644","article-title":"The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery","volume":"72","author":"Sugitani","year":"2025","journal-title":"Endocr J"},{"key":"10.1016\/j.anl.2026.09.003_bib37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2026.09.003_bib38","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","article-title":"A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer","volume":"29","author":"Leboulleux","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2026.09.003_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/thy.2023.0456","article-title":"Clinical outcomes of radioactive iodine redifferentiation therapy in previously iodine refractory differentiated thyroid cancers","volume":"34","author":"Toro-Tobon","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2026.09.003_bib40","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S2213-8587(25)00064-6","article-title":"Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement","volume":"13","author":"Leboulleux","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.anl.2026.09.003_bib41","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1089\/thy.2019.0133","article-title":"Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2026.09.003_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1619875","article-title":"Mutation-based, neoadjuvant treatment for advanced anaplastic thyroid carcinoma","volume":"16","author":"W\u00e4chter","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.anl.2026.09.003_bib43","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/10507256251367286","article-title":"Neoadjuvant therapy with multikinase inhibitors for locally advanced differentiated thyroid cancer: a systematic review","volume":"35","author":"Bauzon","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2026.09.003_bib44","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-25-0024","article-title":"Molecular predictive biomarker testing in advanced thyroid cancer \u2013 a European consensus","volume":"14","author":"Ry\u0161ka","year":"2025","journal-title":"Eur Thyroid J"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814626001422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814626001422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:38:08Z","timestamp":1789731488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814626001422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"alternative-id":["S0385814626001422"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2026.09.003","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular targeted therapy for thyroid cancer in Japan: Current status and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2026.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}